G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) Director Mark A. Velleca sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $13.50, for a total transaction of $270,000.00. Following the sale, the director now directly owns 116,000 shares in the company, valued at approximately $1,566,000. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
G1 Therapeutics Stock Performance
Shares of GTHX stock traded down $0.16 during trading hours on Thursday, hitting $12.77. The company’s stock had a trading volume of 1,388,400 shares, compared to its average volume of 1,003,289. The company has a 50 day moving average of $12.18 and a 200 day moving average of $8.32. The stock has a market cap of $545.88 million, a PE ratio of -3.22 and a beta of 1.93. The company has a current ratio of 4.75, a quick ratio of 4.38 and a debt-to-equity ratio of 1.15. G1 Therapeutics, Inc. has a 12-month low of $3.84 and a 12-month high of $17.49.
G1 Therapeutics (NASDAQ:GTHX – Get Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.12. The business had revenue of $10.57 million for the quarter, compared to the consensus estimate of $9.00 million. G1 Therapeutics had a negative net margin of 608.36% and a negative return on equity of 140.17%. On average, sell-side analysts forecast that G1 Therapeutics, Inc. will post -3.51 EPS for the current fiscal year.
Institutional Trading of G1 Therapeutics
Analysts Set New Price Targets
Several research firms have weighed in on GTHX. HC Wainwright reissued a “buy” rating and set a $67.00 target price on shares of G1 Therapeutics in a research report on Friday, June 3rd. Wedbush boosted their target price on shares of G1 Therapeutics from $20.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 16th. Finally, Needham & Company LLC dropped their target price on shares of G1 Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research report on Thursday, August 4th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $36.83.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
- Get a free copy of the StockNews.com research report on G1 Therapeutics (GTHX)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.